Matthai Mammen, J&J global head of R&D (Rob Tannenbaum, Endpoints News)

J&J posts a sol­id round of pos­i­tive ear­ly da­ta for their BC­MA/CD3 bis­pe­cif­ic teclis­tam­ab, high­light­ing block­buster ex­pec­ta­tions

J&J’s on­col­o­gy R&D team has post­ed promis­ing ear­ly da­ta on one of its block­buster drug can­di­dates in the pipeline.

JNJ-7957, their BC­MA/CD3 bis­pe­cif­ic now called teclis­tam­ab, hit a 67% over­all re­sponse rate among the 12 pa­tients with mul­ti­ple myelo­ma who re­ceived the high­est dose avail­able in their Phase I tri­al. Among those 8 of 12 pa­tients, 3 achieved a com­plete re­sponse, with no vis­i­ble sign of the dis­ease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.